Stephen D Lash, MD | |
3336 S 4155 W, Ste 301, West Valley City, UT 84120 | |
(801) 964-3865 | |
Not Available |
Full Name | Stephen D Lash |
---|---|
Gender | Male |
Speciality | Obstetrics/gynecology |
Experience | 38 Years |
Location | 3336 S 4155 W, West Valley City, Utah |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1447228572 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207VX0000X | Obstetrics & Gynecology - Obstetrics | 90-182235-1205 (Utah) | Primary |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Catholic Health Initiatives Colorado | 8022927342 | 998 |
News Archive
Seattle BioMed today announced that Jason Beaubien, global health and development correspondent of National Public Radio (NPR), will deliver the keynote address at the Passport to Global Health Celebration on March 5.
Businesses are concerned that non-religious employers will end up covering the bill for religious groups that refuse to pay for contraception for their employees. Meanwhile, church leaders continue their push to broaden the exemption from the contraception coverage rule.
Johnson & Johnson revealed Tuesday this week that a clinical trial of its experimental pain drug, fulranumab, has been stopped after the Food and Drug Administration expressed concerns that patients taking the drug could suffer increased joint damage.
Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of Sosei Group Corporation, is pleased to announce that it has entered into a licensing agreement with AstraZeneca under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and potential additional A2A receptor-blocking compounds.
› Verified 9 days ago
Entity Name | Physician Group Of Utah Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1477676930 PECOS PAC ID: 8022032234 Enrollment ID: O20060113000886 |
News Archive
Seattle BioMed today announced that Jason Beaubien, global health and development correspondent of National Public Radio (NPR), will deliver the keynote address at the Passport to Global Health Celebration on March 5.
Businesses are concerned that non-religious employers will end up covering the bill for religious groups that refuse to pay for contraception for their employees. Meanwhile, church leaders continue their push to broaden the exemption from the contraception coverage rule.
Johnson & Johnson revealed Tuesday this week that a clinical trial of its experimental pain drug, fulranumab, has been stopped after the Food and Drug Administration expressed concerns that patients taking the drug could suffer increased joint damage.
Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of Sosei Group Corporation, is pleased to announce that it has entered into a licensing agreement with AstraZeneca under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and potential additional A2A receptor-blocking compounds.
› Verified 9 days ago
Entity Name | Catholic Health Initiatives Colorado |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1942903562 PECOS PAC ID: 8022927342 Enrollment ID: O20230615001995 |
News Archive
Seattle BioMed today announced that Jason Beaubien, global health and development correspondent of National Public Radio (NPR), will deliver the keynote address at the Passport to Global Health Celebration on March 5.
Businesses are concerned that non-religious employers will end up covering the bill for religious groups that refuse to pay for contraception for their employees. Meanwhile, church leaders continue their push to broaden the exemption from the contraception coverage rule.
Johnson & Johnson revealed Tuesday this week that a clinical trial of its experimental pain drug, fulranumab, has been stopped after the Food and Drug Administration expressed concerns that patients taking the drug could suffer increased joint damage.
Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of Sosei Group Corporation, is pleased to announce that it has entered into a licensing agreement with AstraZeneca under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and potential additional A2A receptor-blocking compounds.
› Verified 9 days ago
Mailing Address | Practice Location Address |
---|---|
Stephen D Lash, MD 1060 E 100 S, Suite 400, Salt Lake City, UT 84102-1501 Ph: (801) 521-2640 | Stephen D Lash, MD 3336 S 4155 W, Ste 301, West Valley City, UT 84120 Ph: (801) 964-3865 |
News Archive
Seattle BioMed today announced that Jason Beaubien, global health and development correspondent of National Public Radio (NPR), will deliver the keynote address at the Passport to Global Health Celebration on March 5.
Businesses are concerned that non-religious employers will end up covering the bill for religious groups that refuse to pay for contraception for their employees. Meanwhile, church leaders continue their push to broaden the exemption from the contraception coverage rule.
Johnson & Johnson revealed Tuesday this week that a clinical trial of its experimental pain drug, fulranumab, has been stopped after the Food and Drug Administration expressed concerns that patients taking the drug could suffer increased joint damage.
Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of Sosei Group Corporation, is pleased to announce that it has entered into a licensing agreement with AstraZeneca under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and potential additional A2A receptor-blocking compounds.
› Verified 9 days ago
Alton D Burgett, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3725 W 4100 S, West Valley City, UT 84120 Phone: 801-965-3600 Fax: 801-965-3526 | |
David B Isaac, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 3725 W 4100 S, West Valley City, UT 84120 Phone: 801-965-3600 Fax: 801-965-3526 | |
Maria Alejandra Gonzalez Ferrua, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 3336 S Pioneer Pkwy Ste 301, West Valley City, UT 84120 Phone: 801-964-3865 | |
Lindsay Lawrence, D.O. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3336 S Pioneer Pkwy Ste 301, West Valley City, UT 84120 Phone: 801-964-3865 | |
Steven C Dinger, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 3725 W 4100 S, West Valley City, UT 84120 Phone: 801-965-3600 Fax: 801-965-3526 |